Clinical trial NCT04953910: Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment
Official title: A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes
Lead sponsor: Taiho Oncology, Inc.
Sponsor class: INDUSTRY
First posted: 2021-07-08
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase 1b, multicenter, open-label, pharmacokinetic (PK), and safety study of multiple oral doses of oral decitabine and cedazuridine (formerly known as ASTX727) as a fixed-dose combination of decitabine 35 milligrams (mg) and cedazuridine 100 mg in cancer participants with moderate and severe hepatic impairment and cancer participants with normal hepatic function as control participants. Participants with severe hepatic impairment will be enrolled only after the safety evaluation of at least 6 participants with moderate hepatic impairment has been determined and supports the enrollment of participants with severe hepatic impairment. Adult participants with acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors who are candidates to receive oral decitabine and cedazuridine will be enrolled in this study. Study duration is per participant approximately up to 8 weeks.


Eligibility criteria: Inclusion Criteria:

* Able to understand and comply with the study procedures, understand the risks involved in the study, and provide legally effective informed consent before the first study-specific procedure; specifically able to comply with the PK assessment schedule during the first treatment cycle.
* Participants must have histologically or cytologically confirmed malignancy as follows:

  1. A solid tumor that is metastatic or unresectable and for which standard life-prolonging measures are not available.
  2. AML or MDS.
  3. A hematologic malignancy other than AML or MDS for which standard life-prolonging measures are not available.
* For participants with AML/MDS only:

  1. Cytologically or histologically confirmed diagnosis of AML (except M3 acute promyelocytic leukemia) or MDS according to the 2008 World Health Organization (WHO) classification;
  2. Participants with frontline MDS or treatment naïve AML not suitable for induction therapy (e.g., \>75 years, Eastern Cooperative Oncology Group \[ECOG\] performance status ≥2, severe pulmonary disorder, total bilirubin \>1.5X ULN;
  3. Platelet count ≥25,000/per microliter (μL);
  4. Absolute neutrophil count (ANC) ≥100 cells/μL.
* For participants only with hematologic malignancies other than AML or MDS, or with solid tumors:

  1. Platelet count ≥100,000/μL;
  2. ANC ≥1000 cells/μL.
* ECOG performance status of 0 to 2.
* Hepatic function defined per the National Cancer Institute Cancer Therapy Evaluation Program (NCI CTEP) Organ Dysfunction Working Group (ODWG) as:

  1. Normal hepatic function (Group A): total bilirubin ≤1X ULN; aspartate aminotransferase (AST): ≤1X ULN;
  2. Moderate hepatic impairment (Group B): total bilirubin \>1.5X to 3X ULN; AST: any value;
  3. Severe hepatic impairment (Group C): total bilirubin \>3 times ULN; AST: any value.
* Adequate renal function defined as creatinine clearance (CLcr, according to the Cockcroft-Gault equation) \>50 mL/min.
* No major surgery within 30 days of first administration of oral decitabine and cedazuridine.
* Life expectancy of at least 3 months.
* Women of childbearing potential (according to recommendations of the Clinical Trial Facilitation Group) must not be pregnant or breastfeeding and must have a negative pregnancy test at Screening.
* Women of childbearing potential must agree to practice 1 highly effective contraceptive measure of birth control with low user dependency and must agree not to become pregnant for 6months after completing treatment
* Male participants with female partners of childbearing potential must agree to use a male condom and advise his partner to practice 1 highly effective contraceptive measure of birth control (user dependent or with low user dependency) and must agree not to father a child while receiving treatment with oral decitabine and cedazuridine and for at least 3 months after completing treatment.

Exclusion Criteria:

* Treatment with azacitidine or decitabine within 4 weeks before Screening. Prior cytotoxic chemotherapy for AML except for hydroxyurea to control high white blood cell (WBC) counts.
* Hospitalization for more than 2 days for documented febrile neutropenia, pneumonia, sepsis, or systemic infection 30 days prior to first dose.
* Treatment with any investigational medicinal product (IMP), investigational therapy, chemotherapy, immunotherapy, or targeted therapy within 2 weeks or 5 half-lives, whichever is longer, before the first dose of study treatment, or ongoing clinically significant adverse events from previous treatment.
* Concurrent MDS therapies, including lenalidomide, erythropoietin, cyclosporine/tacrolimus, granulocyte-colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor, etc. Prior treatment with these agents is permitted, provided that completion is at least 1 week before the first dose of study treatment. Short-term use of G-CSF for febrile neutropenia is permitted at the discretion of the treating physician and should be guided by accepted practice or institutional guidelines. Hematopoietic growth factors will not be routinely used unless cleared by Taiho medical expert.
* Administration of live (attenuated) vaccines within 4 weeks before the first administration of oral decitabine and cedazuridine until after the follow-up visit. Other vaccines, e.g., inactivated or ribonucleic acid (RNA)-based, may be administered but should not occur from 7 days before first administration of oral decitabine and cedazuridine until after the follow-up visit.
* High medical risk because of other conditions such as uncontrolled systemic diseases, active uncontrolled infections, or comorbidities that may put the participant at risk of not being able to complete at least 2 cycles of treatment.
* Conditions which likely promote delayed ventricular repolarization (QT prolongation):

  1. Corrected QT interval (QTc) using Fridericia correction (QTcF) at Screening or Day -1 \>450 ms for males and \>470 ms for females.
  2. History or disposition for torsades des pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT Syndrome).
  3. Concomitant medication that prolong the QT/QTc interval.
* Cardiac abnormalities or unstable cardiovascular conditions:

  1. Unstable ischemic heart disease or severe heart failure (New York Heart Association Class III or IV).
  2. Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated measurements for systolic blood pressure ≥180 millimeters of mercury (mmHg) and/or diastolic blood pressure ≥110 mmHg; current or documented history of repeated clinically significant hypotension or severe episodes of orthostatic hypotension (systolic blood pressure \<90 mmHg and/or diastolic blood pressure \<50 mmHg).
* Known significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator predisposes the participant to high risk of noncompliance with the protocol.
* In participants with AML/MDS, rapidly progressive or highly proliferative disease or other criteria that render the participant at high risk of requiring intensive cytotoxic chemotherapy within the next 3 months.
* Life-threatening illness or severe organ system dysfunction, such as uncontrolled congestive heart failure or chronic obstructive pulmonary disease, or other reasons including laboratory abnormalities, which, in the investigator's opinion, could compromise the participant's safety, interfere with the absorption or metabolism of oral decitabine and cedazuridine, or compromise completion of the study or integrity of the study outcomes.
* Untreated central nervous system (CNS) metastases. Participants with treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks before screening.
* Positive nasopharyngeal test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Day -1. Participants may be rescreened if they become SARS-CoV-2 negative.
* Participants infected with human immunodeficiency virus (HIV).
* Positive blood screen for hepatitis C antibody (HCV+) and positive RNA polymerase chain reaction (PCR). Participant can be included if HCV+ but negative for RNA PCR.
* Positive blood screen for hepatitis B surface antigen (HBsAg+). Participants with positive blood screen for hepatitis B surface antibody (HBsAb+) and negative hepatitis B core antibody (HBcAb-) can be included if negative for hepatitis B surface antigen (HBsAg-).
* Average intake of more than 24 units of alcohol per week for male participants and 17 units per week for female participant (1 unit of alcohol equals 10 mL of pure alcohol, i.e., approximately 250 mL of beer, 75 mL of wine, or 25 mL of spirits).
* Positive drugs of abuse or alcohol test at Screening and Day -1, except for the use of prescribed and medically indicated drugs (e.g., benzodiazepines, opiates, or cannabinoids).
* Donation or loss of more than 500 mL of blood within 60 days prior to the first study drug administration.
* Hypersensitivity to decitabine, cedazuridine, or any of the excipients in oral decitabine and cedazuridine.

Primary outcomes:
measure: Pharmacokinetic Parameter: 5-day Cumulative Area Under the Concentration-time Curve Within 1 Dosing Interval (AUCtau)
timeFrame: Predose and at multiple timepoints post-dose from Day 1 to Day 5
Secondary outcomes:
measure: Pharmacokinetic Parameter: Apparent Clearance (CL/F)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Renal Clearance (CLR)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Apparent Nonrenal Clearance (CLNR/F)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Time to Maximum Observed Plasma Concentration (Tmax)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Maximum Observed Plasma Concentration (Cmax)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Area Under the Concentration-time Curve from Time 0 (Time of Dosing) to Time t (AUCt)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Area Under the Concentration-time Curve from Time 0 to 24 Hours (AUC0-24)
timeFrame: Predose and at multiple timepoints post-dose up to 24 hours
measure: Pharmacokinetic Parameter: Area Under the Concentration-time Curve AUC From Time 0 to Infinity (AUC0-inf)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Terminal Elimination Half-life (t1/2)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Apparent Volume of Distribution During Terminal Phase (Vz/F)
timeFrame: Predose from Day 1 to Day 5 and at multiple timepoints post-dose from Day 1 to Day 8
measure: Pharmacokinetic Parameter: Fraction of Administered Drug Excreted into Urine (Fe/F))
timeFrame: Predose and at multiple timepoints post-dose up to 24 hours
measure: Pharmacokinetic Parameter: Cumulative Amount Excreted from Time 0 to the Time of the Last Quantifiable Sample (Aelast)
timeFrame: Predose and at multiple timepoints post-dose up to 24 hours
measure: Safety Parameter: Number of Participants with Adverse Events (AEs)
timeFrame: Up to 8 weeks
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson
state: Texas
city: Yerevan
country: Armenia
facility: Erebuni Medical Center
city: Yerevan
country: Armenia
facility: Hematology Center After Prof. R. Yeolyan (Adult Blood Disorders)
city: Yerevan
country: Armenia
facility: Hematology Center After Prof. R. Yeolyan (Clinic of Adults Oncology)
city: Yerevan
country: Armenia
facility: National Center of Oncology Named After V.A. Fanarjyan
city: Plovdiv
country: Bulgaria
facility: Complex Oncology Center - Plovdiv - Base II
city: Vilnius
country: Lithuania
facility: BIO1
city: Wrocław
country: Poland
facility: Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p.
city: Bucharest
country: Romania
facility: Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu
city: Cluj-Napoca
country: Romania
facility: Institutul Oncologic Prof. Dr. Ion Chiricuta
city: Bratislava
country: Slovakia
facility: Summit Clinical Research s.r.o
city: Barcelona
country: Spain
facility: Hospital Universitari Dexeus - Grupo Quirónsalud
city: Lleida
country: Spain
facility: Hospital Universitari Arnau de Vilanova
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Madrid
country: Spain
facility: Hospital Universitario 12 de Octubre
city: Murcia
country: Spain
facility: Hospital Clínico Universitario Virgen de la Arrixaca (Hematology Dept)
city: Murcia
country: Spain
facility: Hospital Clínico Universitario Virgen de la Arrixaca (Solid Tumor Dept)
city: Valencia
country: Spain
facility: Hospital Universitari i Politècnic La Fe
Study officials:
References: